SCHEMBL5559247

SCHEMBL5559247

COC(=O)c1ccc2[nH]c(-c3nc([N+](=O)[O-])cn3C)nc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.44
RHEB Q15382 1/20 0.43
KDM4E B2RXH2 5/20 0.43
ALDH1A1 P00352 4/20 0.43
RAB9A P51151 4/20 0.43
NPC1 O15118 3/20 0.43
HPGD P15428 3/20 0.43
LMNA P02545 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
PKM P14618 1/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
MMP2 P08253 2/20 0.43
MMP9 P14780 2/20 0.43
MMP8 P22894 2/20 0.43
MMP13 P45452 2/20 0.43
IRAK4 Q9NWZ3 1/20 0.43
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15233334 0.93 BRD4 (0.52) BRD4RHEBKDM4EALDH1A1RAB9A
SCHEMBL7470356 0.88 TDP1 (0.48) KDM4EALDH1A1RAB9ANPC1HPGD
SCHEMBL5559865 0.81 MEN1 (0.47) BRD4RHEBKDM4EALDH1A1RAB9A
SCHEMBL8604250 0.81 HSP90AA1 (0.59) ALDH1A1RAB9ANPC1HPGDSMN1; SMN2
SCHEMBL7467214 0.80 MAPT (0.38) ALDH1A1RAB9AHPGDLMNASMN1; SMN2
Hydrochloric Acid SCHEMBL7466054 0.79 FLT3 (0.38) KDM4ERAB9APKMMMP2MMP9
SCHEMBL1170648 0.78 KDM4E (0.61) BRD4RHEBKDM4EALDH1A1RAB9A
SCHEMBL6523273 0.78 PKN1 (0.38) KDM4EALDH1A1RAB9ANPC1HPGD
SCHEMBL5559555 0.77 KMT2A (0.34) BRD4KDM4EALDH1A1RAB9ANPC1
SCHEMBL8610747 0.77 NPBWR1 (0.60) RHEBKDM4EALDH1A1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8524899-B2 Oligopeptide containing fused 6-membered ring forming complexes with double stranded dna; complexes can be used for identification of specific dsDNA sequences, inhibiting gene transcription, therapeutic for inhibiting proliferation of undesired cells or modulation of expression of specific gene CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2013-09-03 US disclosed
EP-1599474-B1 Heterocyclic oligomeric compounds for DNA recognition CALIFORNIA INST OF TECHN (US) 2013-04-24 EP disclosed
EP-1599474-A4 ALTERNATIVE HETEROCYCLES FOR DNA RECOGNITION CALIFORNIA INST OF TECHN (US) 2007-08-22 EP disclosed
EP-1599474-A2 ALTERNATIVE HETEROCYCLES FOR DNA RECOGNITION CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2005-11-30 EP disclosed
US-20050026174-A1 Alternative heterocycles for DNA recognition CALIFORNIA INSTITUTE OF TECHNOLOGY 2005-02-03 US disclosed
WO-2004078943-A2 ALTERNATIVE HETEROCYCLES FOR DNA RECOGNITION CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2004-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026174-A1 Alternative heterocycles for DNA recognition DDB1, PCNA, DNA2 BRD4 728/4885RHEB 2514/4885KDM4E 4331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.